Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA. ; Division of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, the University of Texas Health Science Center-Houston, Texas, USA.
Clin Med Insights Oncol. 2013 Sep 25;7:247-55. doi: 10.4137/CMO.S12811. eCollection 2013.
Both PCR and Hybrid Capture II (HCII) have been used for identifying cervical dysplasia; however, comparisons on the performance between these two tests show inconsistent results. We evaluated the performance of HCII and PCR MY09/11 in both screening and diagnostic populations in sub-sample of 1,675 non-pregnant women from a cohort in three clinical centers in the United States and Canada.
Sensitivity, specificity, positive predictive value, negative predictive value, and concordance between the two tests were calculated.
Specificity of HCII in detecting low-grade squamous intraepithelial lesion (LSIL) was higher in the screening group (88.7%; 95% CI: 86.2%-90.8%) compared to the diagnostic group (46.3%; 95% CI: 42.1%-50.6%); however, specificity of PCR was low in both the screening (32.8%; 95% CI: 29.6%-36.2%) and diagnostic (14.4%; 95% CI: 11.6%-17.6%) groups. There was comparable sensitivity by both tests in both groups to detect high-grade squamous intraepithelial lesion (HSIL); however, HCII was more specific (89.1%; 95% CI: 86.8%-91.0%; 66.2%; 95% CI: 62.0%-70.1%) than PCR (33.3%; 95% CI: 30.2%-36.5%; 17.9%; 95% CI: 14.8%-21.6%) in the screening and diagnostic groups, respectively. Overall agreement for HPV positivity was approximately 50% between HCII and PCR MY09/11; with more positive results coming from the PCR MY09/11.
In the current study, PCR MY09/11 was more sensitive but less specific than HCII in detecting LSIL, and HCII was more sensitive and specific in detecting HSIL than PCR in both screening and diagnostic groups.
聚合酶链反应(PCR)和杂交捕获 II(HCII)均已用于识别宫颈发育不良;然而,这两种检测方法的性能比较结果不一致。我们评估了 HCII 和 PCR MY09/11 在来自美国和加拿大三个临床中心的队列中 1675 名非妊娠女性亚组的筛查和诊断人群中的性能。
计算了两种检测方法的敏感性、特异性、阳性预测值、阴性预测值和一致性。
HCII 在筛查组中检测低级别鳞状上皮内病变(LSIL)的特异性(88.7%;95%CI:86.2%-90.8%)高于诊断组(46.3%;95%CI:42.1%-50.6%);然而,PCR 在筛查(32.8%;95%CI:29.6%-36.2%)和诊断(14.4%;95%CI:11.6%-17.6%)组中的特异性均较低。两种检测方法在两组中检测高级别鳞状上皮内病变(HSIL)的敏感性相当;然而,HCII 的特异性(89.1%;95%CI:86.8%-91.0%;66.2%;95%CI:62.0%-70.1%)高于 PCR(33.3%;95%CI:30.2%-36.5%;17.9%;95%CI:14.8%-21.6%)在筛查和诊断组中。HCII 和 PCR MY09/11 之间 HPV 阳性的总一致性约为 50%;PCR MY09/11 产生的阳性结果更多。
在本研究中,PCR MY09/11 在检测 LSIL 时比 HCII 更敏感但特异性较低,而 HCII 在筛查和诊断组中检测 HSIL 时比 PCR 更敏感且特异性更高。